The biology of lung cancer

Bull Cancer. 1987;74(5):495-500.

Abstract

Detailed studies of both cell lines and fresh specimens of SCLC and NSCLC have demonstrated that considerable heterogeneity exists within each tumour with respect to morphology and the expression of a range of biomarkers. While retrospective studies suggest that the presence or absence of some of of some of these markers may be of clinical importance, future trials of lung cancer should assess these markers to determine their prospective value in predicting response to therapy, survival and cure from lung cancer.

Publication types

  • Review

MeSH terms

  • Antigens, Neoplasm / immunology
  • Biomarkers, Tumor / analysis
  • Carcinoma, Non-Small-Cell Lung* / analysis
  • Carcinoma, Non-Small-Cell Lung* / genetics
  • Carcinoma, Non-Small-Cell Lung* / immunology
  • Carcinoma, Non-Small-Cell Lung* / pathology
  • Carcinoma, Small Cell* / analysis
  • Carcinoma, Small Cell* / genetics
  • Carcinoma, Small Cell* / immunology
  • Carcinoma, Small Cell* / pathology
  • Cell Line
  • Gene Expression Regulation
  • Humans
  • Lung Neoplasms* / analysis
  • Lung Neoplasms* / genetics
  • Lung Neoplasms* / immunology
  • Lung Neoplasms* / pathology
  • Oncogenes
  • Peptides / analysis
  • Transforming Growth Factors

Substances

  • Antigens, Neoplasm
  • Biomarkers, Tumor
  • Peptides
  • Transforming Growth Factors